Literature DB >> 8077725

Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma.

S Sundar1, F Rosenkaimer, H W Murray.   

Abstract

Fifteen Indian patients with relapsing or drug-refractory visceral leishmaniasis were retreated for 30 days with antimony plus interferon-gamma (IFN-gamma). All 15 had failure of an initial course of antimony and at least one additional course of antimony or pentamidine; 7 patients had failure of three or four prior courses of therapy. During the study, treatment was discontinued in 2 patients because of anemia and congestive heart failure in 1 and intractable vomiting in the other; both subsequently died. In the remaining 13 patients, IFN-gamma plus antimony treatment was associated with daily fever but no other adverse reactions. After 30 days of therapy, 9 (69%) of the 13 patients were apparently cured. Six months after treatment, all 9 were healthy, had parasite-free bone marrow aspirate smears, and were considered cured. None have relapsed during a mean follow-up of 15.9 +/- 1.7 months. These results support the use of antimony plus IFN-gamma as an immunochemotherapeutic alternative for kala-azar patients who have repeated failures of conventional treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077725     DOI: 10.1093/infdis/170.3.659

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

Review 1.  Kala-azar--new developments in diagnosis and treatment.

Authors:  P Aggarwal; R Handa; S Singh; J P Wali
Journal:  Indian J Pediatr       Date:  1999 Jan-Feb       Impact factor: 1.967

Review 2.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  The Leishmania infantum acidic ribosomal protein LiP2a induces a prominent humoral response in vivo and stimulates cell proliferation in vitro and interferon-gamma (IFN-gamma) production by murine splenocytes.

Authors:  M Soto; C Alonso; J M Requena
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

4.  Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.

Authors:  H W Murray; J Hariprashad
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 5.  Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.

Authors:  Shyam Sundar; Neha Agrawal; Bhawana Singh
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-06-17       Impact factor: 4.481

Review 6.  Current and future clinical applications of interferon-gamma in host antimicrobial defense.

Authors:  H W Murray
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

Review 7.  Chemotherapeutics of visceral leishmaniasis: present and future developments.

Authors:  Shyam Sundar; Anup Singh
Journal:  Parasitology       Date:  2017-12-07       Impact factor: 3.234

8.  Visceral leishmaniasis prevalence and associated risk factors in the saran district of Bihar, India, from 2009 to July of 2011.

Authors:  Diana Perry; Kandice Dixon; Rajesh Garlapati; Alex Gendernalik; David Poché; Richard Poché
Journal:  Am J Trop Med Hyg       Date:  2013-02-04       Impact factor: 2.345

9.  Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection.

Authors:  S M B Jeronimo; A K B Holst; S E Jamieson; R Francis; D R A Martins; F L Bezerra; N A Ettinger; E T Nascimento; G R Monteiro; H G Lacerda; E N Miller; H J Cordell; P Duggal; T H Beaty; J M Blackwell; M E Wilson
Journal:  Genes Immun       Date:  2007-08-23       Impact factor: 2.676

10.  Miltefosine (Impavido): the first oral treatment against leishmaniasis.

Authors:  H Sindermann; S L Croft; K R Engel; W Bommer; H J Eibl; C Unger; J Engel
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.